Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Several other equities research analysts have also recently weighed in on ARMP. HC Wainwright set a $7.00 price objective on shares of Armata Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 23rd. LADENBURG THALM/SH SH reissued a “buy” rating and set a $9.00 target price on shares of Armata Pharmaceuticals in a research note on Monday, July 15th.

ARMP stock traded up $0.10 during midday trading on Tuesday, reaching $3.45. 3,973 shares of the company were exchanged, compared to its average volume of 68,156. Armata Pharmaceuticals has a one year low of $2.10 and a one year high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its earnings results on Monday, May 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($1.54).

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply